1 Chagas Disease, the leading cause of heart failure in Latin America, is caused by 2 the kinetoplastid protozoan Trypanosoma cruzi. The sterols of T. cruzi resemble those 3 of fungi, both in composition and biosynthesis. Azole inhibitors of sterol 14α-4 demethylase (CYP51) successfully treat fungal infections in humans and efforts are 5 underway to adapt the success of anti-fungal azoles posaconazole and ravuconazole as 6 second-use agents for Chagas Disease. However, to address concerns about the use 7 of azoles in Chagas Disease, including drug resistance and cost, rational design of non-8 azole CYP51 inhibitors can provide promising alternative drug chemotypes. We report 9 the curative effect of the non-azole CYP51 inhibitor LP10 in an acute mouse model of T. 10 cruzi infection. Mice treated with an oral dose of 40 mg LP10/kg BID for 30 days, 11 initiated 24 hours post infection, showed no signs of acute disease and had 12 histologically normal tissues after 6 months. A very stringent test of cure showed that 13 4/5 mice had negative PCR for T. cruzi, and parasites were amplified by hemoculture in 14 only two treated mice. These results compare favorably with those reported for 15 posaconazole. Electron microscopy and GC-MS analysis of sterol composition 16 confirmed that treatment with LP10 blocked the 14α-demethylation step and induced 17 breakdown of parasite cell membranes culminating in severe ultrastructural and 18 morphological alterations and death of the clinically relevant amastigote stage of the 19 parasite. 20 on November 3, 2017 by guest http://aac.asm.org/ Downloaded from cytochrome P450 enzyme that catalyses oxidative removal of the 14α-methyl group of a 38 sterol precursor to give ∆ 14,15 -desaturated intermediates in ergosterol biosynthesis (19, 39 20). Close similarities to fungi in sterol composition and biosynthesis, plus an absolute 40 requirement for specific 24-methyl sterols for cell viability and proliferation, provide a 41 basis for development of chemotherapy targeting the sterol biosynthetic pathway in T. 42 cruzi. The successful application of antifungal drugs to anti-Chagasic therapy exploits 43 on November 3, 2017 by guest http://aac.asm.org/ Downloaded from 109 MATERIALS AND METHODS 110 Reagents. Recombinant CYP51 Tc was prepared as described elsewhere (8). 111 Compound LP10 (α-[(4-methylcyclohexyl)carbonyl amino]-N-4-pyridinyl-1H-indole-3-112 on November 3, 2017 by guest http://aac.asm.org/ Downloaded from Spectroscopic binding assay. To minimize experimental error, binding assays 130
INTRODUCTION 21
Chagas Disease, caused by the kinetoplastid protozoa Trypanosoma cruzi, is the 22 leading cause of heart failure in Latin America. The disease is naturally transmitted by 23 hematophagous reduviid insects (6), but human infection may also occur via other 24 routes including blood transfusion, congenital infection, breastfeeding, organ transplant 25 from Chagasic donors, laboratory accidents, and ingestion of contaminated foods and 26 beverages. The acute phase of infection usually occurs in children, and 5-10% of 27 symptomatic patients may die. Following a subclinical "indeterminate" phase, a chronic 28 phase involving heart failure and gastrointestinal tract lesions often ensues (37, 42) . 29
The only clinically available drugs for Chagas Disease are nifurtimox and benznidazole. 30
While they have significant efficacy in the acute phase, both drugs have been in use for 31 four decades and suffer from the twin liabilities of serious side effects and low efficacy in 32 the chronic phase. New drugs with improved efficacy and less toxicity are needed (14, 33 29) . 34
The biosynthesis of membrane sterols is one of the metabolic pathways 35 successfully targeted in the treatment of diseases caused by pathogenic fungi (48) . 36
Clinically employed antifungal azoles target sterol 14α-demethylase (CYP51), a 37 these similarities (38) . In addition to compounds optimized for antifungal therapy, other 44 CYP51 inhibitors with strong anti-T. cruzi activity have also been reported (3, 8, 24, 44, 45 45) . 46
Inhibitors of CYP51 are in the pipeline for preclinical and clinical development for 47
Chagas Disease (11). Although earlier commercially available inhibitors like 48 ketoconazole and itraconazole were not powerful enough to eradicate T. cruzi from 49 infected animals or human patients (28), the fourth generation inhibitor posaconazole 50 (Noxafil, Schering-Plough) is capable of inducing parasitological cure in murine models 51 of both acute and chronic Chagas Disease (18). Posaconazole cured between 50-100% 52 of animals in the acute phase and 50-60% of chronically infected animals (2). Very 53 recently, posaconazole cured an immunosuppressed patient with concomitant Chagas 54
Disease and systemic lupus erythematosus (34). However, the use of posaconazole as 55 an anti-Chagasic agent may be limited by the requirement for simultaneous intake of a 56 fatty meal or a nutritional supplement to enhance absorption, the drug's high cost, and 57 the need for clinical monitoring during treatment (31). Another complication is the rapid 58 appearance of laboratory-induced resistance to azoles in T. cruzi, which may predict the 59 occurrence of drug-resistance in Chagasic patients (4). Although no data are available 60 on the development of posaconazole resistance in Chagas Disease patients, studies 61 conducted on fungal infections indicate that posaconazole resistance occurs mainly by 62 a mechanism involving mutation of the cyp51 gene (23, 33, 35). Posaconazole appears 63 to be less susceptible to the efflux pumps that confer resistance to some other azoles 64 in clinical isolates of A. fumigatus (10, 12, 13, 23, 27, 32) (corresponding to G49, P210 68 and F214, respectively, in CYP51 Tc ) and of A61 (46) and P230 (25) in clinical isolates of 69 C. albicans (I45 and P210, respectively, in CYP51 Tc ) map directly to the tunnel mouth 70
where they interact with the dangling long substituent tail of posaconazole extending 71 into the tunnel (9). Mutations of G54 in A. fumigatus to arginine or tryptophan associate 72 with moderate and high levels of resistance, respectively, and confer cross-resistance 73 between itraconazole and posaconazole (27). Mutations of M220 confer cross-74
resistance to all azole drugs tested, including itraconazole, voriconazole, ravuconazole 75 and posaconazole (30, 39) and therefore may interfere with the entry of the drugs. In 76 accordance with this assumption, posaconazole is reported to induce resistance to all 77 azole drugs in Candida parapsilosis in vitro (35). The alarming perspective emerging 78 from antifungal therapy efforts must be taken into consideration when designing anti-79
Chagasic drugs targeting CYP51 Tc . While antifungal azoles do show promise, the less 80 than 30% sequence identity between fungal and protozoan CYP51 targets suggests 81 that a more direct development approach may be a better route toward novel potent 82 therapeutic CYP51 inhibitors. 83
Using clues from our previous work on CYP51 from Mycobacterium tuberculosis 84 (CYP51 Mt ), we focused on rationally designed non-azole inhibitors of T. cruzi CYP51 85 (CYP51 Tc ). These inhibitors were based on an experimental hit obtained from screening 86 a small-molecule compound library against CYP51 Mt (36). Analysis of the x-ray structure 87 revealed that the N-[4-pyridyl]-formamide scaffold group ( Fig.1 , highlighted in grey) 88 binds in the CYP51 active site via conserved residues and the heme prosthetic group. 89 on November 3, 2017 by guest http://aac.asm.org/
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Structural characterization confirmed that these interactions were preserved in the 90 complexes between CYP51 Mt and five different compounds (8, 36), suggesting that this 91 scaffold could be efficiently used instead of the azole or triazole groups to target a 92 variety of chemotypes to the CYP51 active site. Based on the similarity of chemical 93 structures, the second generation compound LP10 ( Fig. 1B) was selected for its 94 nanomolar binding affinity to CYP51 Tc and its potent efficacy against T. cruzi in 95 mammalian cells (8). As the pyridyl group of LP10 presumably coordinates to the heme 96 iron, the imidazole substituent may fill the space occupied by the 2,4-difluorophenyl ring 97 of fluconazole or posaconazole in their structurally characterized complexes with 98 CYP51 (9). 99
In the present work, we evaluated the efficacy of LP10 in an animal model of Waters 2487 dual absorbance detector). 129
The same amounts of DMSO alone were added to a reference cuvette, followed by 136 recording of difference spectra. To determine the K D values, titration data points were 137 fitted to quadratic hyperbola (Equation 1) using the GraphPad PRISM software 138 (Graphpad Software Inc.), where A obs is the absorption shift determined at any ligand 139 concentration; A max is the maximal absorption shift obtained at saturation; K D is the 140 dissociation constant for the inhibitor-enzyme complex; E t is the total enzyme 141 concentration used; S is the ligand concentration. 142
Docking of LP10 in the CYP51 Tc binding site. Molecular docking was 144
performed on the crystal structure of CYP51 (PDB code: 2WUZ) (9) to predict the 145 binding modes of LP10. All docking calculations were carried out using GLIDE with the 146 OPLS2005 force field (21). In order to account for protein flexibility, the induced-fit 147 docking protocol was utilized (40). The S-and R-stereoisomers of LP10 were prepared 148 by the Ligprep module. The rigid receptor grid was first prepared from the crystal 149 structure using the Protein Preparation Wizard module. The receptor then underwent 150 constrained minimization followed by docking in extra-precision (XP) mode (22) in which 151 the van der Waals radii of both protein and ligand were softened by a factor of 0.5 and 152
the Fe 3+ of the heme group was specified for metal constraint. Up to 20 poses for each 153 isomer were subsequently processed to generate their corresponding induced-fit protein 154 receptors. Using PRIME, the side-chain conformations of residues within 5 Å from the 155 docked molecule were predicted before these residues and the ligand were further 156 Blood samples (~150 µl) were obtained by heart puncture prior to animal necropsy. 173
PCR of blood samples (50 µl) was performed as described elsewhere (1) . Hemocultures 174
were initiated with blood cell pellets (75-80 µl), resuspended in 5 ml of BHT medium 175 (17) and maintained for up to 90 days. Cultures were observed weekly by contrast 176 phase microscopy for the presence of T. cruzi epimastigotes. Fifty percent of the BHT 177 medium was replaced every 15 days. Results are summarized in Table 1 .
heat inactivated fetal calf serum in a 5% CO 2 atmosphere at 37° C. For large-scale 182 production of amastigotes, confluent monolayers of BESM cells in 75 cm 2 tissue culture 183 flasks (two flasks per treatment) were infected with 4 x 10 7 parasites/ml for 24 hours. with the aromatic nitrogen of the pyridinyl group. The increased volume of the titration 242 mix (3 ml) and the use of 0.5-µl graduated capillary tubes for adding an inhibitor 243 improved the signal-to-noise ratio and allowed the use of protein concentrations as low 244 as 0.1 µM. An upper limit for the K D values estimated under these conditions was 4.8 245 nM, an order of magnitude lower than previously reported (8). However, as the binding 246 curve still plateaus at a protein: inhibitor ratio of 1:1 (Fig. 2) , true dissociation constants 247 must be lower, perhaps in the picomolar range. Thus, the sensitivity of UV-vis 248 on November 3, 2017 by guest http://aac.asm.org/ Downloaded from spectroscopy sets a lower limit for accurate K D determination at ~0.1 µM. Compounds 249 with higher binding affinities cannot be discriminated by the standard UV-vis assay. 250
Computational docking of the S-and R-stereoisomers of LP10 predicted different 251 binding modes to CYP51 Tc (Fig. 3) . The binding affinities of both isomers to CYP51 Tc 252 are predicted to be similar, as the GLIDE XP docking scores for the S-and R-isomers 253 are, respectively, -8.9 and -9.3. These calculations predict that the indole ring of the R-254 isomer will fill the space occupied by the 2,4-difluorophenyl ring of fluconazole or 255 posaconazole in their structurally characterized complexes with CYP51 (9). Stacking 256 interactions with the aromatic residues Y103, Y116, F100 and the heme macrocycle will 257 contribute to this binding mode ( Fig. 3 A) . The indole ring of the S-isomer is predicted to 258 bind in the hydrophobic pocket formed by the residues M106, L208, F290, H294, L356, 259 M460 and V461 (Fig. 3 B) . As shown in prior work, the interactions of the indole ring are hemocultures of LP10-treated mice was discarded due to contamination) ( Table 1) . 282
Inhibition of 14α α α α-demethylation by LP10. To confirm that LP10 targets 283 CYP51 tc , we analyzed sterol composition in T. cruzi extracts from both intracellular 284 amastigotes cultured in BESM cells and axenically cultured insect epimastigotes. 285
Cultures were either untreated or treated with LP10 or posaconazole. Examples of GC-286 MS traces are shown for amastigotes ( Fig. 4) and epimastigotes (Fig. 5) . Untreated, T. 287 cruzi-infected BESM cells ( Fig. 4 A) were used as a positive control and non-infected 288 BESM cells (Fig. 4 D) as an additional control to compare with amastigote-infected cells 289 treated with 5 µM LP10 (Fig. 4 B) or posaconazole (Fig. 4 C) for 72 h. Similarly, 290 epimastigotes were either untreated ( Fig. 5 A) , treated with LP10 ( Fig. 5 B) or 291 posaconazole (Fig. 5 C) . 292
The sterol identities were assigned based on relative chromatographic behavior 293 as well as the characteristic molecular masses and fragmentation patterns (Figs. 4, 5,  294 on November 3, 2017 by guest http://aac.asm.org/ Downloaded from Appendix Fig. 1A-3A , and Appendix Table A2 ). Our assignments are similar to those 295 reported elsewhere (26, 41). Identified sterols are, I: lanosterol (4,4,14 -296 trimethylcholesta-8,24-dien-3β-ol); II: eburicol (24-methylenedihydrolanosterol); III: 297 fecosterol (ergosta-8,24(24')-dien-3β-ol); IV: episterol (ergosta-7,24(24')-dien-3β-ol); V: 298 4-methyl-ergosta-8,14,24(24')-trienol: VI: 4-methylepisterol (4-methylcholesta-7,24(24')-299 dien-3β-ol); VII: ergosterol (ergosta-5,7,22-trien-3β-ol). Fecosterol and its ∆8-∆7 isomer 300 episterol were identified as principal sterols in the untreated amastigotes, where no ∆5 301 sterols or ergosterol have been detected. This observation is consistent with the results 302 reported elsewhere (26, 43). The untreated epimastigotes revealed a richer pool of 303 sterols, compared to amastigotes, consisting of a mix of ergosterol, episterol, fecosterol 304 and 14-desmethyl intermediates 4-methyl-ergosta-8,14,24(24')-trienol and 4-305 methylepisterol. Exogenous cholesterol is present in both epimastigote and amastigote 306 samples (Fig. 4, 5) . 307
Both LP10 and posaconazole induced similar changes in sterol composition in T. 308 cruzi amastigotes and epimastigotes. In amastigotes, treatment with either of the two 309 inhibitors at 5 µM for 72 h resulted in complete depletion of fecosterol and a significant 310 reduction in episterol content with concomitant accumulation of lanosterol and eburicol 311 precursors ( Fig. 4 B and C) . Similar effects were observed in epimastigotes. Although 312 the pool of the 14-demethylated sterols in the membranes of untreated epimastigotes is 313 more diversified than in amastigotes ( Fig. 5 A) , they virtually disappeared upon 314 treatment with posaconazole ( Fig. 5 C) . Residual amounts of ergosterol were detected 315 in the LP10-treated epimastigotes (Fig. 5 B) . These overall results indicate that LP10, T. cruzi amastigote and epimastigote sterol biosynthetic pathways were partially 319 reconstructed from the sterols identified experimentally (Fig. 6) . The pathway appears 320 straightforward in amastigotes ( Fig. 6 A) while branching is required to explain the more 321 complex composition of the identified sterols in epimastigotes (Fig. 6 B) . 322
Alterations in T. cruzi amastigote ultrastructure. A forty eight hour treatment 323
with CYP51 inhibitors induced major changes in the ultrastructure of amastigote cells, 324
including blebbing of the cell membrane, swelling of the nuclear membrane, and 325 appearance of large autophagic-like vesicles (Fig. 7) . Finally, a 72 h treatment with 326 
